|Bid||1.2500 x 900|
|Ask||1.2900 x 1000|
|Day's Range||1.2200 - 1.3400|
|52 Week Range||0.5500 - 7.5000|
|Beta (5Y Monthly)||1.89|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Growing concern about the emergence of monkeypox in Europe and the U.S. has sent shares soaring for several vaccine and drug companies. At least three cases have been confirmed in the U.S. over the past year, including one in an adult male who recently traveled from Canada to Massachusetts. Several companies that developed smallpox vaccines or therapeutics have seen their shares prices jump, and some of those drug makers may be familiar to investors who paid close attention to stocks that got a boost in early 2020 after China first disclosed the outbreak of the new coronavirus that was eventually identified as SARS-CoV-2.
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
The U.S. Patent and Trademark Office has issued Patent No. 11,311,612 covering GeoVax Labs Inc's (NASDAQ: GOVX) modified vaccinia Ankara (MVA) vector expressing certain antigens from the malaria parasite. GeoVax's MVA-VLP malaria vaccine candidates incorporate antigens derived from multiple stages of the parasite's life cycle. They are designed to induce an immune response with durable functional antibodies and CD4+ and CD8+ T cell responses. GeoVax's GV-MVA-VLP vaccine platform utilizes modifie